CEL SCI CORP (CVM) Form 8-K — May 14, 2026
CEL-SCI Corporation (NYSE American: CVM) has entered into a strategic partnership with Saudi Amarox Co. for the regulatory affairs, marketing, and commercialization of its investigational immunotherapy Multikine in Saudi Arabia. The agreement grants Amarox exclusive distribution rights in the Kingdom, with an optional extension to other Gulf Cooperation Council (GCC) countries, contingent upon approval from the Saudi Food and Drug Authority (SFDA). The parties will share net revenue from Multikine sales on a 50/50 basis.
Key figures
- Agreement term
- 5 years initial, renewable
- Revenue share split
- 50/50
- Patients dosed multikine
- 740
- Market size saudi immunotherapy 2033
- $2.7 billion
Price after filing
Close on the filing date to close N calendar days later (from $1.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.